Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

On CNBC's “ Halftime Report Final Trades ,” Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC said Sabra ...

The FDA approved Amgen's Uplizna as the first treatment for IgG4-RD. The decision is backed by the MITIGATE trial, showing reduced flares and sustained efficacy.

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Shares of Amgen Inc. (NASDAQ:AMGN – Get Free Report) have earned a consensus recommendation of “Hold” from the twenty-four ...

The FDA’s decision to grant Breakthrough Therapy Designation to UPLIZNA underscores the significant unmet medical need in ...

In this wide and deep sector, though, there are some notable exceptions. Let's take a look at two outliers with dividend policies that have looked especially attractive lately -- pharmaceutical ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

Let's discuss whether Amgen or Merck stock offers better value. The price-to-earnings (P/E) ratio is a financial metric that divides a stock's price by its earnings per share (EPS) as a quick way ...